Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $200.6 million.

  • Fulcrum Therapeutics' Cash & Equivalents rose 17625.64% to $200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.6 million, marking a year-over-year increase of 17625.64%. This contributed to the annual value of $241.0 million for FY2024, which is 203.2% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Cash & Equivalents of $200.6 million as of Q3 2025, which was up 17625.64% from $214.1 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Cash & Equivalents ranged from a high of $241.0 million in Q4 2024 and a low of $30.1 million during Q3 2023
  • In the last 5 years, Fulcrum Therapeutics' Cash & Equivalents had a median value of $65.5 million in 2021 and averaged $98.7 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Cash & Equivalents crashed by 6693.33% in 2022, and later surged by 57303.27% in 2023.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Cash & Equivalents stood at $35.4 million in 2021, then dropped by 0.89% to $35.1 million in 2022, then skyrocketed by 573.03% to $236.2 million in 2023, then rose by 2.03% to $241.0 million in 2024, then decreased by 16.75% to $200.6 million in 2025.
  • Its Cash & Equivalents stands at $200.6 million for Q3 2025, versus $214.1 million for Q2 2025 and $226.6 million for Q1 2025.